Medical Research, Diagnostic Substances and Life Science Tools

August 16, 2013

Buy ($175)

Topics covered: Health Care Growth Sectors Identified, Health Care Consolidation Activity, Cost Reduction and Improving Efficiencies, Cost Reduction Amid Reimbursement Uncertainty

Companies covered: AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), Enzo Biochem, Inc. (NYSE:ENZ), Navidea Biopharmaceuticals, Inc. (NYSEAMERICAN:NAVB), CEPHEID (NASDAQ:CPHD), Thermo Fisher Scientific Inc (NYSE:TMO), Sequenom, Inc. (NASDAQ:SQNM), Siemens AG (OTCMKTS:SIEGY), Quidel Corporation (NASDAQ:QDEL), Luminex Corporation (NASDAQ:LMNX), Life Technologies Corporation, Laboratory Corporation of America Holdings (NYSE:LH), Johnson & Johnson (NYSE:JNJ), Illumina, Inc. (NASDAQ:ILMN), Hologic, Inc. (NASDAQ:HOLX), Genomic Health, Inc. (NASDAQ:GHDX), Abbott Laboratories (NYSE:ABT), Walgreen Co., MedAssets, Inc. (NASDAQ:MDAS), ICON plc (NASDAQ:ICLR), Express Scripts Holding Company (NASDAQ:ESRX), CVS Health Corporation (NYSE:CVS), Cardinal Health, Inc. (NYSE:CAH), AmerisourceBergen Corporation (Holding Co) (NYSE:ABC), Agilent Technologies, Inc. (NYSE:A)